CoMentis and Purdue Research Foundation settle dispute
Published: May 9, 2012
SOUTH SAN FRANCISCO, Calif. and WEST LAFAYETTE, Ind. – CoMentis, Inc., a privately held biopharmaceutical company engaged in the development of drugs to treat Alzheimer's disease, and Purdue Research Foundation, a private, nonprofit foundation serving Purdue University, announced Wednesday (May 9) that they had settled their litigation over certain drug compounds and intellectual property relating to beta-secretase inhibitors.
The litigation had been pending in federal district court in the Northern District of Indiana. In accordance with the terms of the settlement, the parties have agreed to discontinue the litigation immediately and dismiss all claims and counterclaims against each other.
CoMentis, Inc. is headquartered in South San Francisco, Calif., with research operations in both South San Francisco and Oklahoma City, Okla. The company is engaged in the discovery and development of small-molecule drugs to treat Alzheimer's disease. For more information: www.comentis.com
About Purdue Research Foundation
The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University. Established in 1930, the foundation accepts gifts, administers trusts, funds scholarships and grants and acquires property on behalf of Purdue. In the 1990s, the foundation was charged with helping the university in the realm of economic development. The Purdue Research Foundation oversees the Purdue Research Park, which is the largest university-affiliated business incubation complex in the country.
Purdue Research Foundation contact:
Cynthia Sequin, (765) 588-3340, email@example.com